Table 2. Univariate and multivariate analyses for progression-free survival.
BMI, body mass index; HR, hazard ratio; NACT; neoadjuvant chemotherapy; NLR, neutrophil-to-lymphocyte ratio; PDS; primary debulking surgery; FIGO: International Federation of Gynecology and Obstetrics; CA-125: cancer antigen-125; LG includes endometrioid carcinoma, clear cell carcinoma, mucinous carcinoma, and low-grade serous carcinomas; HG includes high-grade serous carcinomas.
| Characteristics | Category | Univariate | Multivariate | |
| P-value | HR (95% CI) | P-value | ||
| Age | ≥47 vs. <47 years | 0.894 | 0.60 (0.22-1.63) | 0.316 |
| Parity | Multiparous vs. nulliparous | 0.013 | 4.63 (1.39-15.39) | 0.012 |
| Menopausal status | Postmenopause vs. premenopause | 0.632 | - | - |
| BMI | ≥24.0 vs. <24.0 kg/m2 | 0.990 | - | - |
| Serum CA-125 levels | ≥112.0 vs. <112.0 U/mL | 0.401 | 1.30 (0.36-4.68) | 0.687 |
| Comorbidity | Yes vs. No | 0.069 | 2.77 (0.91-8.40) | 0.072 |
| Upfront primary treatment | NACT vs. PDS | 0.366 | 0.71 (0.23-2.15) | 0.539 |
| Ascites | Yes vs. No | 0.294 | 0.91 (0.34-2.40) | 0.848 |
| FIGO stage | Advanced vs. early | 0.296 | 1.19 (0.25-5.74) | 0.824 |
| Surgical debulking status | Optimal vs. suboptimal | 0.952 | - | - |
| Histological subtype | HG vs. LG | 0.958 | - | - |
| Pretreatment NLR | ≥2.23 vs. <2.23 years | 0.033 | 2.43 (0.95-6.27) | 0.065 |